MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$38,365K
EPS
-$0.63
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Research and development
24,788
34,355*
30,457
35,816
General and administrative
14,768
10,811*
8,270
8,594
Total operating expenses
39,556
45,166
38,727
44,410
Loss from operations
-39,556
-45,166*
-38,727
-44,410
Interest income
1,929
2,549*
2,000
2,364
Interest expense
674
458*
7
14
Other expense, net
-18
26*
-53
-21
Total other income, net
1,237
2,117*
1,940
2,329
Net loss
-38,319
-43,050
-36,787
-42,081
Unrealized loss on available-for-sale marketable securities, net
-46
-
49
-19
Total other comprehensive loss
-46
-
49
-19
Net loss and other comprehensive loss
-38,365
-
-36,738
-42,100
Basic EPS
-0.63
-0.933
-0.85
-0.97
Diluted EPS
-0.63
-0.933
-0.85
-0.97
Basic Average Shares
60,896,872
46,139,265
43,415,367
43,225,365
Diluted Average Shares
60,896,872
46,139,265
43,415,367
43,225,365
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss and other
comprehensive loss
-$38,365K
(8.87%↑ Y/Y)
Interest income
$1,929K
(-18.40%↓ Y/Y)
Net loss
-$38,319K
(8.94%↑ Y/Y)
Total other
comprehensive loss
-$46K
(-142.11%↓ Y/Y)
Total other income,
net
$1,237K
(-46.89%↓ Y/Y)
Interest expense
$674K
(4714.29%↑ Y/Y)
Other expense, net
-$18K
(14.29%↑ Y/Y)
Loss from operations
-$39,556K
(10.93%↑ Y/Y)
Unrealized loss on
available-for-sale marketable...
-$46K
(-142.11%↓ Y/Y)
Total operating
expenses
$39,556K
(-10.93%↓ Y/Y)
Research and development
$24,788K
(-30.79%↓ Y/Y)
General and
administrative
$14,768K
(71.84%↑ Y/Y)
Buy us a coffee
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)